Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy
批准号:
10229223
负责人:
Aaron J Johnson
金额:
$193.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2024-03-31
关键词:
APP-PS1AblationAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAntigen PresentationAntigen-Presenting CellsAntigensAreaArizonaAttentionAuthorshipBehavioralBiological ModelsBlood - brain barrier anatomyBrainCD4 Positive T LymphocytesCD69 antigenCD8-Positive T-LymphocytesCD8B1 geneCellsCellular biologyCerebrovascular systemClinicCognitive deficitsCollaborationsCore FacilityDementiaDendritic CellsDevelopmentDiseaseDissectionDocumentationEnvironmentExperimental ModelsFundingGene ExpressionGene Expression ProfilingGoalsGrantGranzymeHistocompatibility Antigens Class IHumanImageImmuneInfectionInfiltrationInflammationInvestigationJointsKnockout MiceKnowledgeMHC Class I GenesMagnetic Resonance ImagingManuscriptsMechanicsMethodologyMicrogliaModelingMonitorMusNIH Program AnnouncementsNerve DegenerationNeurologicNeuronsParentsPatientsPhenotypeProteinsRecombinant adeno-associated virus (rAAV)ResearchResearch PersonnelRoleSeminalSeverity of illnessSystemT cell responseT-Lymphocyte SubsetsTauopathiesTechnologyTestingTransgenic MiceVascular PermeabilitiesWell in selfWorkblood-brain barrier disruptionbrain cellbrain parenchymacell typecerebral atrophyconditional knockoutdesigneffector T cellinnovationmacrophagemouse modelnervous system disorderneuroinflammationneuropathologynovelperforinprogramsresponserole modeltherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT - Alzheimer’s disease (AD) and other neurodegenerative conditions are characterized by
heightened inflammation, neurodegeneration, and CNS vascular permeability, including microhemorrhage
formation. The role of specific immune cell types in the underlying neuropathology associated with AD and
other neurologic diseases remains an active area of research. Significant attention has been given to the role
of innate immune cells and microglia in the development of AD. However, the role of adaptive immune cells,
including CD8 T cells, has not been defined despite their presence in brain parenchyma of AD patients. These
findings were further accentuated by the recent analysis of CD8 T cell repertoire and correlation with disease
severity in human AD patients. APP/PS1 mice revealed significant brain infiltration of CD8 T cells of effector
phenotype. Similarly, our Co-investigator, Dr. John Fryer of Mayo Clinic Arizona, has also observed significant
CD8 T cell brain infiltration in his novel rAAV initiated tauopathy mouse model. Using our novel MHC class I
conditional knockout mice, we have determined that macrophages and dendritic cells prime non-equivalent
CD8 T cell responses in response to PbA infection. While both antigen presenting cells prime CD8 T cell
response that infiltrate the brain, only CD8 T cells raised by dendritic cells induce lethal blood-brain barrier
disruption. Our central hypothesis that clonally expanded CD8 T cells engage brain vasculature and
migratory antigen presenting cells during infiltration which contributes to neuropathology and
cognitive deficits in AD and Tauopathies. We plan to test this central hypothesis through execution of the
following specific aims:
Specific Aim 1 – Define the CD8 T cell repertoire and phenotype(s) generated in APP/PS1 and
Tauopathy mice through transcriptional profiling.
Specific Aim 2 – Determine critical role of residential and migratory APCs in priming and enabling CNS
infiltration of CD8 T cell responses in APP/PS1 and Tauopathy mouse models
Specific Aim 3 – Dissect the critical MHC class I expressing CNS cell type required for CD8 T cell
induced neuropathology and cognitive deficits
The proposed work is innovative because it capitalizes on our unique transgenic mouse models, novel imaging
methodology, and new core facilities available to our research program at Mayo Clinic. Our goal is to define
mechanistically the contribution of CD8 T cells in human dementia through knowledge gained using leading
experimental models. Beyond the innovative methodology employed, the concept that antigen presenting
cells raise differential CD8 T cell responses is highly novel and warrants further investigation to a mechanism
which is therapeutically targetable. This is especially important if CD8 T cell priming and engagement of
antigen presented by specific cell types is promoting neuropathology and behavioral deficits.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
-
批准号:10836880
-
项目类别:
-
资助金额:$6.13万
-
财政年份:2023
-
负责人:Aaron J Johnson
-
依托单位:
CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions
-
批准号:10609855
-
项目类别:
-
资助金额:$41.21万
-
财政年份:2017
-
负责人:Aaron J Johnson
-
依托单位:
CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions
-
批准号:9392836
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2017
-
负责人:Aaron J Johnson
-
依托单位:
CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions
-
批准号:10199061
-
项目类别:
-
资助金额:$41.21万
-
财政年份:2017
-
负责人:Aaron J Johnson
-
依托单位:
CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions
-
批准号:10391533
-
项目类别:
-
资助金额:$41.21万
-
财政年份:2017
-
负责人:Aaron J Johnson
-
依托单位:
Immune Contribution to Brain Atrophy
-
批准号:9272449
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2016
-
负责人:Aaron J Johnson
-
依托单位:
CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions
-
批准号:9293869
-
项目类别:
-
资助金额:$39.75万
-
财政年份:2016
-
负责人:Aaron J Johnson
-
依托单位:
Enhancing Glioma-Specific Immunity
-
批准号:8750352
-
项目类别:
-
资助金额:$17.29万
-
财政年份:2014
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:8306282
-
项目类别:
-
资助金额:$33.7万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:8509031
-
项目类别:
-
资助金额:$32.45万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:8160750
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:8204842
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:7730340
-
项目类别:
-
资助金额:$35.21万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
CD 8 T Cell Mediated Disruption of Blood Brain Tight Junction
-
批准号:7897667
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:Aaron J Johnson
-
依托单位:
海外基金